Eli Lilly stock rises after hours as fresh GLP-1 stop data revives a big question ahead of earnings

Eli Lilly and Company shares gained roughly 0.8% in after-hours Thursday, last seen at $1,087.38, up $8.81. During the session, the stock fluctuated between $1,072.46 and $1,095.15.

23 January 2026

Johnson & Johnson stock price today: JNJ ends higher, but talc case stays in focus after earnings

Johnson & Johnson shares ended Thursday roughly 0.3% higher at $218.49, after moving between $217 and $221.86 during the session. Trading volume hit around 13 million shares.

22 January 2026

Earnings Reports·NYSE:JNJ·Pharmaceutical Industry·Stock Market

Johnson & Johnson stock price swings late as JNJ guidance beats views, but talc risk grabs traders again

Johnson & Johnson shares dipped 0.05% to $218.01 in after-hours trading Wednesday, swinging from a low of $209.20 to a high of $218.61. Investors balanced the company’s 2026 forecast with fresh scrutiny over talc-related lawsuits.

22 January 2026

Earnings Reports·NYSE:JNJ·Pharmaceutical Industry·Stock Market

Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

Eli Lilly’s stock jumped 3.6% on Wednesday, finishing at $1,078.52. The boost came after the company announced that the U.S. Food and Drug Administration awarded Breakthrough Therapy designation to its experimental ovarian cancer drug.

21 January 2026

Earnings Reports·NYSE:LLY·Pharmaceutical Industry·Stock Market

RAPT stock hovers near $58 as GSK buyout puts tender offer clock in focus

RAPT Therapeutics held steady on Wednesday, trading around $57.60 midday on Nasdaq. The shares ticked up just 0.05% during the session.

21 January 2026

NASDAQ:RAPT·NYSE:GSK·Pharmaceutical Industry·Stock Market

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

Merck & Co’s stock ended Tuesday 0.57% higher, closing at $109.45, supported by long-term data on a personalized melanoma vaccine it’s working on with Moderna, which helped steady investor sentiment as the session wrapped up.

21 January 2026

Earnings Reports·NASDAQ:GH·NASDAQ:MRNA·NYSE:MRK·Pharmaceutical Industry·Stock Market

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

Rapt Therapeutics surged roughly 64% to $57.57 in after-hours trading Tuesday following news that Britain’s GSK will acquire the U.S. biotech.

21 January 2026

LSE:GSK·NASDAQ:RAPT·Pharmaceutical Industry·Stock Market

Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

ImmunityBio’s IBRX shares ended Friday at $5.52, jumping roughly 40% following a series of company updates that attracted momentum traders. Trading volume surged past 182 million shares.

18 January 2026

NASDAQ:IBRX·Pharmaceutical Industry·Stock Market

Johnson & Johnson stock is sleepy today — earnings next week may decide the next move

Johnson & Johnson shares dipped slightly on Friday, showing more resilience than many peers in the healthcare sector ahead of the company’s earnings report next week. The stock slipped around 0.1% to $219.38, fluctuating between $218.43 and $220.14 during the session.

16 January 2026

Earnings Reports·NYSE:JNJ·Pharmaceutical Industry·Stock Market

Johnson & Johnson stock price edges higher after hours as Tecvayli data and earnings loom

Johnson & Johnson shares rose about 0.5% in after-hours trading on Thursday to $219.57, after swinging between $215.93 and $219.73 during the regular session.

16 January 2026

Earnings Reports·NYSE:JNJ·Pharmaceutical Industry·Stock Market

Merck stock slips as FDA fast-track delays grab attention ahead of Feb. 3 earnings

Shares of Merck & Co slipped 0.2% to $110.75 on Thursday, fluctuating within a range of $108.48 to $111.06 during the day.

15 January 2026

Earnings Reports·NYSE:MRK·Pharmaceutical Industry·Stock Market

Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

Shares of Edgewise Therapeutics Inc were up 10.6% at $27.59 by 12:55 p.m. EST on Wednesday after the drug developer laid out a 2026 schedule for clinical readouts and trial starts across its muscle-disease and cardiac pipeline.

14 January 2026

NASDAQ:EWTX.O·Pharmaceutical Industry·Stock Market

Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data

Shares of Erasca Inc jumped roughly 10% Wednesday, pushing higher after a string of price-target upgrades fueled by early trial results. The clinical-stage cancer drugmaker's stock hit $8.29, up 10.5%.

14 January 2026

Biotechnology·NASDAQ:ERAS·Pharmaceutical Industry·Stock Market

Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Pfizer shares dipped 0.6% to $25.12 by mid-afternoon Tuesday, continuing a volatile stretch for the drugmaker as investors digested its recent comments on obesity treatments. The stock fluctuated between $24.98 and $25.42 during the session.

13 January 2026

Earnings Reports·NYSE:PFE·Pfizer·Pharmaceutical Industry

Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

Atara Biotherapeutics shares plunged about 56% to $6.03 in early trading after the U.S. Food and Drug Administration rejected its cell therapy tabelecleucel, marketed as EBVALLO in Europe, for a rare post-transplant cancer. The stock was volatile, swinging between $4.77 and $15.40 as investors reacted to the news, with volume exceeding 1.4 million shares.

12 January 2026

NASDAQ:ATRA·Pharmaceutical Industry·Stock Market

Liquidia stock jumps after $148.3 million YUTREPIA sales update — what LQDA investors watch next week

Shares of Liquidia Corporation jumped 12.9% to close at $35.86 on Friday, following a strong sales surge for its inhaled treprostinil therapy, YUTREPIA. The stock traded between $29.41 and $38.07 throughout the day.

11 January 2026

Earnings Reports·NASDAQ:LQDA·Pharmaceutical Industry·Stock Market

Thermo Fisher Scientific Inc stock: Weaverville phase-out plan hits tape ahead of JPM talk, Jan. 29 earnings

Thermo Fisher Scientific is set to wind down its Weaverville-area facility in western North Carolina, according to a WARN notice filed with the state. The document reveals permanent layoffs starting as early as Dec. 31, 2026, with the eventual closure slated for late 2027. The company plans to cut 421 jobs at its 275 Aiken Road site, beginning the first wave of separations at the end of 2026 and continuing through the following year.

10 January 2026

Earnings Reports·NYSE:TMO·Pharmaceutical Industry·Stock Market

AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie Inc. shares dropped 1.8% on Friday, closing at $220.08. The decline followed the drugmaker’s decision to lower its 2025 earnings forecast and a denial of reports suggesting it was in talks to acquire cancer-drug developer Revolution Medicines. Since 2023, AbbVie has spent over $20 billion on acquisitions, aiming to offset the impact from Humira’s patent expiration.

10 January 2026

NASDAQ:RMD·NYSE:ABBV·Pharmaceutical Industry·Stock Market

Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in

Eli Lilly and Co shares fell nearly 2% on Friday, closing at $1,063.56, after swinging between about $1,063 and $1,104 in the session. The stock was little changed after hours.

9 January 2026

NYSE:LLY·Pharmaceutical Industry

Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

Shares of Revolution Medicines climbed on Friday as investors weighed a report that Merck is in talks to buy the cancer-drug developer for up to $32 billion. Revolution was up about 4.3% at $112.00, after touching $125.79 earlier in the session.

9 January 2026

NASDAQ:RVMD·Pharmaceutical Industry·Stock Market

Previous 1 2 3 4 5 6 … 10 Next

Johnson & Johnson stock price today: JNJ ends higher, but talc case stays in focus after earnings

Johnson & Johnson stock price swings late as JNJ guidance beats views, but talc risk grabs traders again

Eli Lilly stock rises as FDA gives ‘Breakthrough’ tag to ovarian cancer drug, earnings date set

RAPT stock hovers near $58 as GSK buyout puts tender offer clock in focus

Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

Why ImmunityBio stock jumped nearly 40%: ANKTIVA sales surge and a fresh trial timeline

Johnson & Johnson stock is sleepy today — earnings next week may decide the next move

Johnson & Johnson stock price edges higher after hours as Tecvayli data and earnings loom

Merck stock slips as FDA fast-track delays grab attention ahead of Feb. 3 earnings

Edgewise Therapeutics stock jumps about 11% on 2026 trial calendar — what’s next for EWTX

Erasca stock jumps 10% as Wall Street lifts targets to $11 on ERAS-0015 data

Pfizer stock slips as CEO likens obesity drugs to Viagra; Metsera trials and Feb. 3 earnings in focus

Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next

Liquidia stock jumps after $148.3 million YUTREPIA sales update — what LQDA investors watch next week

Thermo Fisher Scientific Inc stock: Weaverville phase-out plan hits tape ahead of JPM talk, Jan. 29 earnings

AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

Eli Lilly stock drops 2% as Zepbound arthritis data and Ventyx deal sink in

Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

TechStock² Updates

American Airlines Shares Dip 1.2% With $92 Oil Squeezing Earnings Margins

Nasdaq Futures Fall 1.2% as 10-Year Treasury Yield Approaches 4.8%

Netflix’s The Secret Woman Hits No. 2 as $25 Billion Content Commitments Face a Returns Test

Energy Soars 3.3% With Oil Approaching $92; QQQ Declines

NIO Stock Drops 1.2% as Revenue Guide Slows to 4.8% Growth

SCHD up 24%, yield trails Treasuries by 1.6 points

Nu Holdings Falls 1.2% Before Market Open as P/E Multiple Outpaces Bank Rivals

Oracle Stock Falls 3.1% as Layoff Report Highlights $55.7 Billion Capital Bill

Oklo Shares Dip 1.2% Before Market Open as 23 Million-Share Offering Overshadows Insider Selling

Oil Steady Over $92 While Nasdaq Futures Drop 1%

Investment Disclaimer